The program will build on established and new collaborations, including ongoing activities in computational modeling of biological systems in cooperating MIT departments, and will represent a closely integrated collaborative effort between cancer biologists (cell and molecular biologists and geneticists) and computationally sophisticated modelers to analyze the properties and behavior of cancer cells in vitro and in intact animals and to generate refinable and portable computational models of cancer progression. The program will focus on the use of murine models of cancer progression to generate genome-scale data sets on the genes and proteins associated with the various steps in cancer progression. These data sets will be analyzed for reproducible patterns. Filtered data from the in vivo models, as well as from cell culture models derived from them, will be used as substrates for generation of computational models for cellular programs contributing to individual aspects of cancer progression. These will include both cell-intrinsic programs as well as programs responding to inputs to the cancer cells from their surroundings. Areas of initial concentration for modeling will include: cellular responses to growth factors, cell-matrix adhesion and DNA damage as well as cell polarization and migration. An important component of the program will be testing of the computational models by perturbation of the in vivo and cellular model systems by RNA interference and, where appropriate, genetic engineering of the mice harboring the cancer models. This testing will lead to validation and refinement of the computational models. This cycle of data generation and analysis, computational modeling and validation/refinement will be repeated to develop increasingly robust and rich models of cancer cells functioning in their environment. Training and education of interdisciplinary scientists conversant with the different approaches and their effective integration will be an integral part of the program and will include the development of new courses and educational activities to complement those already in place at MIT.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112967-04
Application #
7286774
Study Section
Special Emphasis Panel (ZCA1-GRB-V (O1))
Program Officer
Gallahan, Daniel L
Project Start
2004-09-30
Project End
2009-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
4
Fiscal Year
2007
Total Cost
$2,649,567
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Internal Medicine/Medicine
Type
Schools of Arts and Sciences
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Kulkarni, Madhura; Tan, Tuan Zea; Syed Sulaiman, Nurfarhanah Bte et al. (2018) RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9:14175-14192
Miller, Miles A; Sullivan, Ryan J; Lauffenburger, Douglas A (2017) Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res 23:623-629
Nagel, Zachary D; Kitange, Gaspar J; Gupta, Shiv K et al. (2017) DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res 77:198-206
Oudin, Madeleine J; Barbier, Lucie; Schäfer, Claudia et al. (2017) MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther 16:143-155
Bruno, Peter M; Liu, Yunpeng; Park, Ga Young et al. (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461-471
Werbin, Jeffrey L; Avendaño, Maier S; Becker, Verena et al. (2017) Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Sci Rep 7:12150
White, Forest M; Wolf-Yadlin, Alejandro (2016) Methods for the Analysis of Protein Phosphorylation-Mediated Cellular Signaling Networks. Annu Rev Anal Chem (Palo Alto Calif) 9:295-315
Wilson, Jennifer L; Dalin, Simona; Gosline, Sara et al. (2016) Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integr Biol (Camb) 8:761-74
Zhao, Boyang; Hemann, Michael T; Lauffenburger, Douglas A (2016) Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends Cancer 2:144-158
Tuncbag, Nurcan; Milani, Pamela; Pokorny, Jenny L et al. (2016) Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Sci Rep 6:28668

Showing the most recent 10 out of 222 publications